A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors

Antiviral Research

Volumn 84, Issue 2, 2009, Pages 178-184

  Chase, Robert ^a   Skelton, Angela ^a   Xia, Ellen ^a   Curry, Stephanie ^a   Liu, Shaotang ^a   McMonagle, Patricia ^a   Huang, H C ^a   Tong, Xiao ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Combination therapy; HCV polymerase inhibitor; HCV protease inhibitor; Resistance

Indexed keywords

2' METHYLADENOSINE; ALPHA INTERFERON; BOCEPREVIR; INDOLE N ACETAMIDE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; NUCLEOTIDYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; REPLICON; SEQUENCE ANALYSIS; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HEPACIVIRUS; HUMANS; MUTATION; PROLINE; PROTEASE INHIBITORS; REPLICON; RNA REPLICASE; SERIAL PASSAGE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 70349568585     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.09.003     Document Type: Article

References (31)

1. Beaulieu P.L. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr. Opin. Invest. Drugs 8 (2007) 614-634
2. Blight K.J., Kolykhalov A.A., and Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 290 (2000) 1972-1974
3. Bressanelli S., Tomei L., Roussel A., Incitti I., Vitale R.L., Mathieu M., De Francesco R., and Rey F.A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 13034-13039
4. Carroll S.S., and Olsen D.B. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. Disord. Drug Targets 6 (2006) 17-29
5. Flint M., Mullen S., Deatly A.M., Chen W., Miller L.Z., Ralston R., Broom C., Emini E.A., and Howe A.Y. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob. Agents Chemother. 53 (2009) 401-411
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 (2002) 975-982
7. Gane E.J., Roberts S.K., Stedman C., Angus P.W., Ritchie B., Elston R., Ipe D., Baher L., Morcos P., Najera I., Mannino M., Brennan B., Berrey M., Bradford W., Yetzer E., Shulman N., and Smith P.F. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. J. Hepatol. 50 Suppl 1 (2009) S380
8. Godofsky E.W., Afdhal N., Rustgi V., Shick L., Duncan L., Zhou X.L., Chao G., Fang C., Fielman B., Myers M., and Brown N.A. First clinical results for a novel antiviral treatment for hepatitis C: a phase I/II dose escalation trial assessing tolerance, pharmacokinetics and antiviral activity on NM283, a novel antiviral treatment for hepatitis C. Gastroenterology 126 (2004) A681
9. Harper S., Pacini B., Avolio S., Di Filippo M., Migliaccio G., Laufer R., De Francesco R., Rowley M., and Narjes F. Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. J. Med. Chem. 48 (2005) 1314-1317
10. Kneteman N.M., Howe A.Y., Gao T., Lewis J., Pevear D., Lund G., Douglas D., Mercer D.F., Tyrrell D.L., Immermann F., Chaudhary I., Speth J., Villano S.A., O'Connell J., and Collett M. HCV796: a selective non-structural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 49 (2009) 1-9
11. Krieger N., Lohmann V., and Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75 (2001) 4614-4624
12. Kukolj G., McGibbon G.A., McKercher G., Marquis M., Lefebvre S., Thauvette L., Gauthier J., Goulet S., Poupart M.A., and Beaulieu P.L. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J. Biol. Chem. 280 (2005) 39260-39267 (Epub 32005 September 39227)
13. Lesburg C.A., Cable M.B., Ferrari E., Hong Z., Mannarino A.F., and Weber P.C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6 (1999) 937-943
14. Ludmerer S.W., Graham D.J., Boots E., Murray E.M., Simcoe A., Markel E.J., Grobler J.A., Flores O.A., Olsen D.B., Hazuda D.J., and LaFemina R.L. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob. Agents Chemother. 49 (2005) 2059-2069
15. Malcolm B.A., Liu R., Lahser F., Agrawal S., Belanger B., Butkiewicz N., Chase R., Gheyas F., Hart A., Hesk D., Ingravallo P., Jiang C., Kong R., Lu J., Pichardo J., Prongay A., Skelton A., Tong X., Venkatraman S., Xia E., Girijavallabhan V., and Njoroge F.G. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 50 (2006) 1013-1020
16. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
17. McCown M.F., Rajyaguru S., Le Pogam S., Ali S., Jiang W.R., Kang H., Symons J., Cammack N., and Najera I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to non-nucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 52 (2008) 1604-1612 (Epub 2008 February 1619)
18. Migliaccio G., Tomassini J.E., Carroll S.S., Tomei L., Altamura S., Bhat B., Bartholomew L., Bosserman M.R., Ceccacci A., Colwell L.F., Cortese R., De Francesco R., Eldrup A.B., Getty K.L., Hou X.S., LaFemina R.L., Ludmerer S.W., MacCoss M., McMasters D.R., Stahlhut M.W., Olsen D.B., Hazuda D.J., and Flores O.A. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278 (2003) 49164-49170
19. Morrison J.F., and Walsh C.T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61 (1988) 201-301
20. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
21. Reed K.E., and Rice C.M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol.: Hepatitis C Viruses 242 (2000) 55-84
22. Sarrazin C., Rouzier R., Wagner F., Forestier N., Larrey D., Gupta S.K., Hussain M., Shah A., Cutler D., Zhang J., and Zeuzem S. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 non-responders. Gastroenterology 132 (2007) 1270-1278
23. Taremi S.S., Beyer B., Maher M., Yao N., Prosise W., Weber P.C., and Malcolm B.A. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci. 7 (1998) 2143-2149
24. Tomei L., Altamura S., Bartholomew L., Biroccio A., Ceccacci A., Pacini L., Narjes F., Gennari N., Bisbocci M., Incitti I., Orsatti L., Harper S., Stansfield I., Rowley M., De Francesco R., and Migliaccio G. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77 (2003) 13225-13231
25. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., and Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral. Res. 70 (2006) 28-38
26. Tong X., Bogen S., Chase R., Girijavallabhan V., Guo Z., Njoroge F.G., Prongay A., Saksena A., Skelton A., Xia E., and Ralston R. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral. Res. 77 (2008) 177-185 (Epub 2007 December 2028)
27. Villano S., Howe A., Raible D., Harper D., Speth J., and Bichier G. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients. Hepatology 44 (2006) 607A
28. Villano S.A., Raible D., Harper D., Speth J., Chandra P., Shaw P., and Bichier G. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment-naive patients with chronic HCV. J. Hepatol. 46 (2007) S24
29. Zeuzem S., Sarrarin C., Rouzier R., Tarral A., Brion N., Forestier N., Gupta S., Deckman D., Fellows K., Hussain M., Cutler D., and Zhang J. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in HCV-1 patients refractory to pegylated interferon (PEG-IFN-α). Hepatology 42 (2005) 233A
30. Zeuzem S., Sarrarin C., Wagner F., Rouzier R., Forestier N., Gupta S., Hussain M., Shah A., Cutler D., and Zhang J. Combination therapy with HCV protease inhibitor SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron non-responders. Hepatology 42 (2005) 276A
31. Zhang R., Beyer B.M., Durkin J., Ingram R., Njoroge F.G., Windsor W.T., and Malcolm B.A. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal. Biochem. 270 (1999) 268-275